
### **Developers by Headquarter Region** and Therapeutic Approach






Within-graph labels represent headquarter region totals
Developers may work across multiple therapeutic approaches; sum of therapeutic approach totals will not be equivalent to regional totals
Please see "Methodology Notes" for additional details

# **Developers by Headquarter Region and Entity Type**






1. Within-graph labels represent headquarter region totals

# **Developers by Entity Type** and Therapeutic Approach






Within-graph labels represent entity type totals
Developers may work across multiple therapeutic approaches; sum of therapeutic approach totals will not be equivalent to entity type totals
Please see "Methodology Notes" for additional details

# **Developers by Entity Type and Headquarter Region**






1. Within-graph labels represent entity type totals

# **Developers by Therapeutic Approach** and Entity Type






Within-graph labels represent therapeutic approach totals
Developers may work across multiple therapeutic approaches; sum of therapeutic approach totals will not be equivalent to entity type totals
Please see "Methodology Notes" for additional details

### **Developers by Therapeutic Approach** and Headquarter Region





Within-graph labels represent therapeutic approach totals
Developers may work across multiple therapeutic approaches; sum of therapeutic approach totals will not be equivalent to regional totals
Please see "Methodology Notes" for additional details

#### **Methodology Notes for Developer Data**



#### Methodology Notes

1. Developer data represent a snapshot in time; this snapshot was taken in August 2023.

2. \*Developer data consist of the primary owners of a therapeutic drug or platform considered to be part of the durable regenerative medicine sector by ARM. This includes cell, gene, gene-modified cell (GMCT), and tissue engineering therapies.

2a. As durability is a key scoping factor, ARM typically excludes non-durable treatments where possible (antisense-based gene therapies, vaccines). Notable exceptions: Krystal Bio's topical cream, Vyjuvek.

2b. In other reports, ARM typically allocates GMCTs to gene therapy or cell-based immunooncology (CBIO), based on indication. As indication is not present in this dataset, that allocation is not possible here.

3. \*Developer headquarter regions are based on the location of the parent headquarters of a company, whenever known, at the highest definition of 'Parent Company' available. For single-entity and/or single-location developers, the company is considered its own parent.

4. Therapeutic developers may have multiple therapeutic approaches in their pipeline and/or portfolio; the sum of therapeutic approach totals may not be equivalent to developer totals.

\* Updated in 2023